AIM Vaccine Management
Management criteria checks 3/4
AIM Vaccine's CEO is Yan Zhou, appointed in Sep 2020, has a tenure of 4.25 years. total yearly compensation is CN¥2.18M, comprised of 86.5% salary and 13.5% bonuses, including company stock and options. directly owns 16.62% of the company’s shares, worth HK$1.23B. The average tenure of the management team and the board of directors is 3.6 years and 4.4 years respectively.
Key information
Yan Zhou
Chief executive officer
CN¥2.2m
Total compensation
| CEO salary percentage | 86.5% |
| CEO tenure | 4.3yrs |
| CEO ownership | 16.6% |
| Management average tenure | 3.6yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt
Nov 15
Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge
Aug 24It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)
May 29Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking
Jun 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥1b |
| Mar 31 2024 | n/a | n/a | -CN¥1b |
| Dec 31 2023 | CN¥2m | CN¥2m | -CN¥1b |
| Sep 30 2023 | n/a | n/a | -CN¥913m |
| Jun 30 2023 | n/a | n/a | -CN¥525m |
| Mar 31 2023 | n/a | n/a | -CN¥422m |
| Dec 31 2022 | CN¥2m | CN¥2m | -CN¥320m |
| Dec 31 2021 | CN¥899m | CN¥1m | -CN¥693m |
Compensation vs Market: Yan's total compensation ($USD298.01K) is below average for companies of similar size in the Hong Kong market ($USD481.95K).
Compensation vs Earnings: Yan's compensation has increased whilst the company is unprofitable.
CEO
Yan Zhou (57 yo)
4.3yrs
Tenure
CN¥2,175,000
Compensation
Mr. Yan Zhou is Executive Chairman and Chief Executive Officer of AIM Vaccine Co., Ltd. September 2020. He has served as a Director of AIM Vaccine Co., Ltd.since May 2015 and was re-designated as an execu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 4.3yrs | CN¥2.18m | 16.62% HK$ 1.2b | |
| Executive Vice-Chairman & Executive President | 11.6yrs | no data | 3.3% HK$ 245.2m | |
| Vice-Chairman of the Board & Executive President | 3.8yrs | CN¥2.23m | no data | |
| Executive Director & Executive President | less than a year | no data | 3.3% HK$ 245.2m | |
| COO, Executive President & Executive Director | 3.8yrs | CN¥2.43m | 0.84% HK$ 62.3m | |
| Chief Financial Officer | 9.2yrs | no data | no data | |
| Secretary & Chief Investment Officer | 9.1yrs | no data | no data | |
| Chief Research Officer | 3.8yrs | no data | no data | |
| Chief Quality Officer | 2.7yrs | no data | no data | |
| Chief Public Affairs Officer | 2.8yrs | no data | no data | |
| Chief Marketing Officer | 2.8yrs | no data | no data | |
| Joint Company Secretary | 3.5yrs | no data | no data |
3.6yrs
Average Tenure
54yo
Average Age
Experienced Management: 6660's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 9.6yrs | CN¥2.18m | 16.62% HK$ 1.2b | |
| Executive Vice-Chairman & Executive President | 11.6yrs | no data | 3.3% HK$ 245.2m | |
| Vice-Chairman of the Board & Executive President | 3.8yrs | CN¥2.23m | no data | |
| Executive Director & Executive President | 9.6yrs | no data | 3.3% HK$ 245.2m | |
| COO, Executive President & Executive Director | 7.3yrs | CN¥2.43m | 0.84% HK$ 62.3m | |
| Independent Non-Executive Director | 4.3yrs | CN¥300.00k | no data | |
| Chairman of The Supervisory Committee | 3.8yrs | no data | no data | |
| Independent Non-Executive Director | 3.6yrs | CN¥300.00k | no data | |
| Non-Executive Director | 7.3yrs | no data | 4.13% HK$ 306.5m | |
| Independent Non-Executive Director | 3.8yrs | CN¥300.00k | no data | |
| Non-Executive Director | 4.5yrs | no data | no data | |
| Independent Non-Executive Director | 3.6yrs | CN¥300.00k | no data |
4.4yrs
Average Tenure
58yo
Average Age
Experienced Board: 6660's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 10:50 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AIM Vaccine Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tony Ren | Macquarie Research |